Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis

Metabolic syndrome is a type of multifactorial metabolic disease with the presence of at least three factors: obesity, diabetes mellitus, low high-density lipoprotein, hypertriglyceridemia, and hypertension. Recent studies have shown that metabolic syndrome and its related components exert a signifi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 629666
Main Authors Dong, Shuwen, Wang, Zheng, Shen, Kunwei, Chen, Xiaosong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 25.03.2021
Subjects
breast cancer
incidence
metabolic syndrome
obesity
Oncology
prognosis
treatment response
metabolic syndrome
breast cancer
incidence
prognosis
treatment response
obesity
Online AccessGet full text

Cover

More Information
Summary:Metabolic syndrome is a type of multifactorial metabolic disease with the presence of at least three factors: obesity, diabetes mellitus, low high-density lipoprotein, hypertriglyceridemia, and hypertension. Recent studies have shown that metabolic syndrome and its related components exert a significant impact on the initiation, progression, treatment response, and prognosis of breast cancer. Metabolic abnormalities not only increase the disease risk and aggravate tumor progression but also lead to unfavorable treatment responses and more treatment side effects. Moreover, biochemical reactions caused by the imbalance of these metabolic components affect both the host general state and organ-specific tumor microenvironment, resulting in increased rates of recurrence and mortality. Therefore, this review discusses the recent advances in the association of metabolic syndrome and breast cancer, providing potential novel therapeutic targets and intervention strategies to improve breast cancer outcome.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Masahiko Tanabe, University of Tokyo, Japan; Luca Gelsomino, University of Calabria, Italy
These authors have contributed equally to this work
This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology
Edited by: Carmine De Angelis, University of Naples Federico II, Italy
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.629666